Sanofi-Aventis Pipeline Includes Sleep Quality Aid, Depression Therapy
Executive Summary
Positive early clinical results for Sanofi-Aventis' sleep disorder therapy eplivanserin could lead to the development of a "new concept" for improving quality of sleep, Senior Exec VP-Science & Medical Affairs Gerard Le Fur said
You may also be interested in...
Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron
In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews.
Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron
In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews.
Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron
In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews